| Compound | Selank |
|---|---|
| Category | Tuftsin-derived anxiolytic peptide |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Selank — a tuftsin-derived anxiolytic peptide — sits in the "Minimal evidence" tier of this catalog. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A synthetic peptide based on the immune-active sequence tuftsin, registered in Russia as an anxiolytic. Like Semax, its evidence base is largely regional.
Mechanism of Action
Selank is reported to modulate GABAergic and serotonergic signaling and to influence enkephalin degradation in animal work.
Research and Evidence
Small Russian clinical studies in anxiety disorders have been published; no trials meeting international registrational standards are available.
Safety and Side Effects
Regional registered use describes mild effects; unregulated product quality is the main practical concern.
Frequently Asked Questions
What is the evidence tier of Selank?
Selank is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Selank an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Selank?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for Selank studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.